Brief Report: HIV-1 Infection Impairs CD16 and CD35 Mediated Opsonophagocytosis of Mycobacterium tuberculosis by Human Neutrophils.
Using a flow cytometric assay, we investigated neutrophil-Mycobacterium tuberculosis opsonophagocytosis and the impact of HIV-1-infected serum on this process. The mean (±SD) percentage of neutrophils internalizing bacilli after 30 minutes incubation was significantly reduced by pretreatment with anti-CD16 (18.2% ± 8.1%, P < 0.001) or anti-CD35 antibody (23.2% ± 10.6%, P < 0.05) versus anti-CD4 controls (29.9% ± 8.1%). Blocking CD88 or CD11a did not affect internalization. Using heat-inactivated serum, maximal internalization was lower using HIV-1-infected serum versus HIV-1-uninfected. Using non-heat-inactivated serum, internalization decreased more rapidly with sequential dilutions of HIV-1-infected versus HIV-1-uninfected serum. CD16 and CD35 are important for neutrophil internalization of M. tuberculosis, whereas HIV-1 infection adversely affects opsonophagocytosis.
*Clinical Infectious Diseases Research Initiative, Institute for Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa; †Institute of Tropical Medicine, Antwerp, Belgium; ‡Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) Uganda Research Unit on AIDS, Entebbe, Uganda; §Blizard Institute, Barts and The London School of Medicine, Queen Mary University of London, London, United Kingdom; ‖Department of Medicine, Imperial College London, London, United Kingdom; ¶Mill Hill Laboratory, The Francis Crick Institute, London, United Kingdom; and #Institute of Immunity and Transplantation, University College London, London, United Kingdom.
Nonzwakazi
N
Bangani
Justine
J
Nakiwala
Adrian R
AR
Martineau
Robert J
RJ
Wilkinson
Katalin A
KA
Wilkinson
David M
DM
Lowe
D018791:CD4 Lymphocyte Count; D005434:Flow Cytometry; D058851:GPI-Linked Proteins / Q000378:metabolism; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology; D009169:Mycobacterium tuberculosis / Q000276:immunology*; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology*; D009895:Opsonin Proteins / Q000378:metabolism*; D010587:Phagocytosis / Q000187:drug effects / Q000276:immunology*; D017463:Receptors, Complement 3b / Q000378:metabolism*; D017452:Receptors, IgG / Q000378:metabolism*; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology; D019562:Viral Load
C509991:CR1 protein, human; C428200:FCGR3B protein, human; D058851:GPI-Linked Proteins; D007155:Immunologic Factors; D009895:Opsonin Proteins; D017463:Receptors, Complement 3b; D017452:Receptors, IgG